Aura Biosciences, Inc. AURA Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Aura Biosciences, Inc. in its filing.
Tagged under the XBRL concept aura:AccruedExpensesAndOtherCurrentLiabilities.
The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aura Biosciences, Inc.'s accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aura Biosciences, Inc.'s accrued expenses and other current liabilities?
- Aura Biosciences, Inc. (AURA) reported accrued expenses and other current liabilities of $10.87M in Q1 2026.
- How has Aura Biosciences, Inc.'s accrued expenses and other current liabilities changed year-over-year?
- Aura Biosciences, Inc.'s accrued expenses and other current liabilities increased by 55.6% year-over-year, from $6.99M to $10.87M.
- What is the long-term trend for Aura Biosciences, Inc.'s accrued expenses and other current liabilities?
- Over 5 years (2020 to 2025), Aura Biosciences, Inc.'s accrued expenses and other current liabilities has grown at a 46.0% compound annual growth rate (CAGR), from $2.05M to $13.59M.
- What does accrued expenses and other current liabilities mean?
- This metric represents the aggregate of short-term financial obligations that have been incurred but not yet invoiced or paid by the end of the reporting period. It typically includes items such as accrued compensation, professional fees, and other operational costs essential to maintaining clinical-stage research activities. Monitoring this balance provides insight into the company's near-term cash outflow requirements and the timing of its operational expenditures.